ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 0423 • ACR Convergence 2021

    Urine and Plasma Complement Ba Levels During Flares of Nephritis in Patients with ANCA-Associated Vasculitis

    Salem Almaani1, Huijuan Song2, Meshora Sthanithra2, Christopher Toy2, Anna Levesque2, Lynn Fussner3, Alexa Meara3, Haikady Nagaraja2, David Cuthbertson4, Nader Khalidi5, CURRY LEE MD KOENING6, Carol Langford7, Carol McAlear8, Larry Moreland9, Christian Pagnoux10, Philip Seo11, Antoine Sreih12, Kenneth Warrington13, Paul Monach14, Peter Merkel8, Brad Rovin3 and Dan Birmingham2, 1Ohio State University Medical Center, Columbus, OH, 2Ohio State university, Columbus, OH, 3Ohio State University Wexner Medical Center, Columbus, OH, 4University of South Florida, Tampa, FL, 5McMaster University, Hamilton, ON, Canada, 6LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, 7Cleveland Clinic, Moreland Hills, OH, 8University of Pennsylvania, Philadelphia, PA, 9University of Colorado, Denver, CO, 10Mount Sinai Hospital, Toronto, ON, Canada, 11Johns Hopkins University, Baltimore, MD, 12Univeristy of Pennsylvania, Philadelphia, PA, 13Mayo Clinic, Rochester, Minnesota, 14Brigham and Women's Hospital, Boston, MA

    Background/Purpose: The alternative complement pathway has been implicated in the pathogenesis of ANCA-associated vasculitis (AAV), however it is not clear whether activation of complement occurs…
  • Abstract Number: 0800 • ACR Convergence 2021

    Digital Spatial Profiling Reveals Distinct Synovial Tissue Transcriptomic Signature of Sustained Disease Remission in Rheumatoid Arthritis Patients at Risk of Disease Flare After Treatment Tapering or Discontinuation

    Stefano Alivernini1, Simone Perniola2, Marco Gessi3, Maria Rita Gigante4, Clara Di Mario5, Luca Petricca4, Dario Bruno5, Laura Bui1, Annamaria Paglionico1, Valentina Varriano1, Maria Antonietta D'Agostino6, Barbara Tolusso1 and Elisa Gremese7, 1Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 2Fondazione Policlinico Universitario A. Gemelli IRCCS - University of Verona, Santeramo in Colle, Italy, 3Fondazione PoliclinicoUniversitario A. Gemelli IRCCS, Rome, Italy, 4Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 5Division of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy, 6Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, 7Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy

    Background/Purpose: Sustained disease remission is the treatment goal for Rheumatoid Arthritis (RA) leading patients to be eligible to treatment tapering or discontinuation. However, disease flare…
  • Abstract Number: 1204 • ACR Convergence 2021

    CXCL13 Outranges DAS28CRP and CRP as Predictor of Long-term Radiographic Status in Early Rheumatoid Arthritis

    Stinne Greisen1, Merete Hetland2, Mikkel Ostergaard3, Kim Horslev-Petersen4, Peter Junker5, Kristian Stengaard-Petersen6, Malene Hvid1 and Bent Deleuran1, 1Aarhus University, Aarhus, Denmark, 2DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, 3Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, 4King Christian 10th Hospital for the Rheumatic Diseases, and University of Southern Denmark, Aabenraa, Denmark, 5Department of Rheumatology, Odense University Hospital, Odense C, Denmark, 6Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: In a cohort of early rheumatoid arthritis (eRA) patients, we recently showed that early and aggressive treatment led to remission and limited erosive progression…
  • Abstract Number: 1381 • ACR Convergence 2021

    Chemokines CCL2 and CCL17 as Potential Serum Biomarkers for Interstitial Lung Disease in Systemic Sclerosis

    Imon Barua1, Håvard Fretheim2, Hilde Jenssen Bjørkekjær3, Henriette Didriksen4, Oyvind Midtvedt2, Trond Mogens AAløkken2, Torhild Garen5, Oyvind Molberg6, John Belperio7 and Anna-Maria Hoffmann-Vold1, 1Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 2Oslo University Hospital, Oslo, Norway, 3Department of Rheumatology, Sørlandet sykehus HF, Kristiansand, Norway, 4Oslo University Hospital, Moss, Norway, 5Department of Rheumatology, Oslo University Hospital, Oslo, Nepal, 6Oslo University Hospital, Oslo, Nepal, 7University of California Los Angeles Interstitial Lung Disease Center, Los Angeles, CA

    Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD). Several anti-inflammatory therapies have been used to treat SSc-ILD and recently the…
  • Abstract Number: 1736 • ACR Convergence 2021

    Treatment of Lupus Nephritis with Belimumab Is Associated with Reduction in Urinary CD23

    Emma Weeding1, Andrea Fava2, Chandra Mohan3, Daniel Goldman4 and Michelle Petri4, 1Johns Hopkins Hospital, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3University of Houston, Houston, TX, 4Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Urine proteomic approaches have shown promise in identifying dynamic biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by…
  • Abstract Number: 0323 • ACR Convergence 2021

    Ro Positivity Is an Under‐Recognised Poor Prognostic Marker in Systemic Lupus Erythematosus Patients

    Katie Liao1, Thilinie De Silva1, Julie Bonin2, Rachel Koelmeyer2 and Alberta Hoi3, 1Department of Rheumatology, Monash Health, Melbourne, Australia, 2Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, 3Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia

    Background/Purpose: Antibodies to Ro60 (SSA) or Ro52 (SSB) have been described as one of the defining autoantibodies in Sjogren syndrome but they are also commonly…
  • Abstract Number: 0442 • ACR Convergence 2021

    Identification of Plexin D1 on Circulating Extracellular Vesicles as a Potential Biomarker of Polymyositis and Dermatomyositis

    Kenichi Uto1, Koji Ueda2, Takaichi Okano1, Kengo Akashi1, Soshi Takahashi3, Yuji Nakamachi4, Takamitsu Imanishi1, Seiji Kawano1, Yoshihiko Yano5 and Jun Saegusa6, 1Kobe University Hospital, Kobe, Japan, 2Japanese Foundation for Cancer Research, Tokyo, Japan, 3Shinko Hospital, Kobe, Japan, 4Kobe University School of Medicine, Kobe, Japan, 5Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan, 6Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan

    Background/Purpose: Extracellular vesicles (EVs), including exosomes and microvesicles, are small membrane vesicles released by almost all cell types and are found circulating in blood and…
  • Abstract Number: 0848 • ACR Convergence 2021

    Automatic Hand Segmentation from Hand X-rays Using Minimized Training Samples and Machine Learning Models

    Zilong Yang1, Juan Shan2, Carmine Guida2, Jordan Blackadar1, Tino Cheung1, Jeffrey Driban3, Timothy McAlindon4 and Ming Zhang1, 1Wentworth Institute of Technology, Boston, MA, 2Pace University, New York, NY, 3Tufts Medical Center, Boston, MA, 4Tufts Medical Center, Arlington, MA

    Background/Purpose: In many hand osteoarthritis (OA) studies (e.g., automatic Joint Space Width measuring), accurate hand segmentation is the first step towards making further analysis. However,…
  • Abstract Number: 1206 • ACR Convergence 2021

    Serum Levels of Total IgA Anti-cyclic Citrullinated Protein Antibodies Predict 11-year Radiographic Outcome in Early Rheumatoid Arthritis

    Elisabeth Rasmussen1, Liv Thiele1, Kristian Stengaard-Pedersen2, Merete Hetland3, Kim Horslev-Petersen4, Peter Junker5, Mikkel Ostergaard6, Aida Hansen1, Malene Hvid1, Bent Deleuran1 and Stinne Greisen1, 1Aarhus University, Aarhus, Denmark, 2Aarhus University Hospital, Aarhus, Denmark, 3DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, 4Danish Hospital for Rheumatic Diseases, Haderslev, Denmark, 5Department of Rheumatology, Odense University Hospital, University of Southern Denmark, Odense M, Denmark, 6Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by polyarticular synovitis and frequent occurrence of autoantibodies, playing a central role in disease progression. Anti-citrullinated peptide antibodies (ACPA)…
  • Abstract Number: 1384 • ACR Convergence 2021

    A Genomic Meta-Analysis of Clinical Variables and Association with Intrinsic Molecular Subsets in Systemic Sclerosis

    Jennifer Franks1, Diana Toledo1, Viktor Martyanov1, Yue Wang2, Suiyuan Huang3, Tammara Wood1, Cathie Spino3, Robyn Domsic4, Monique Hinchcliff5, Dinesh Khanna3 and Michael Whitfield6, 1Geisel School of Medicine at Dartmouth, Hanover, NH, 2Geisel School of Medicine at Dartmouth, West Lebanon, NH, 3University of Michigan, Ann Arbor, MI, 4University of Pittsburgh, Pittsburgh, PA, 5Yale School of Medicine, Westport, CT, 6Geisel School of Medicine, Lebanon, NH

    Background/Purpose: Four intrinsic molecular subsets (Inflammatory, Fibroproliferative, Limited, Normal-like) have been identified in systemic sclerosis (SSc) that may have different clinical associations. To test this…
  • Abstract Number: 1737 • ACR Convergence 2021

    Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial

    Emma Weeding1, Andrea Fava2, Chandra Mohan3, Daniel Goldman4 and Michelle Petri4, 1Johns Hopkins Hospital, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3University of Houston, Houston, TX, 4Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Urinary CD163 is a macrophage marker which correlates with histological activity index and response to treatment in lupus nephritis (LN), as evidenced by urine…
  • Abstract Number: 0325 • ACR Convergence 2021

    A Multianalyte Assay Panel with Cell-bound Complement Activation Products Demonstrates Clinical Utility for the Diagnosis and Treatment of Systemic Lupus Erythematosus

    Roberta Alexander1, Scott Rey1, John Conklin1, Vinicius Domingues2, Mansoor Ahmed3, Jazibeh Qureshi4 and Arthur Weinstein5, 1Exagen Inc., Vista, CA, 2Florida State university, Daytona beach, FL, 3Arthritis Osteo Ctr of KY, Richmond, KY, 4Rheumatology Express, Catonsville, MD, 5Loma Linda University (Voluntary Position), Claremont, CA

    Background/Purpose: The multianalyte assay panel (MAP) consists of cell-bound complement activation products (CB-CAPs) with lupus and non-lupus autoantibodies combined in an algorithm (Dervieux et al.,…
  • Abstract Number: 0449 • ACR Convergence 2021

    Identification of Serum Protein Biomarkers at Baseline to Distinguish Radiographic Progressors from Non-Progressors in Patients with Active Psoriatic Arthritis

    Orla Coleman1, Bruna Wundervald2, Ruoyi Zhou3, James Waddington3, Robert LJ Graham4, Ciaren Graham4, Geoff McMullan4, Andrew C. Parnell5, Vinod Chandran6, Philip Mease7, Gaia Gallo8, Venkatesh Krishnan8, Stephen Pennington9 and Oliver FitzGerald10, 1Atturos, Bray, Ireland, 2Atturos, Maynooth, Ireland, 3Atturos, Belfield, Ireland, 4Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom, 5Maynooth University, Maynooth, Ireland, 6Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 7Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 8Eli Lilly and Company, Indianapolis, IN, 9University College Dublin, Dublin, Ireland, 10Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland

    Background/Purpose: A delay in diagnosis and management of patients with PsA leads to poor radiographic and functional outcomes [1]. The need to identify which patients…
  • Abstract Number: 0868 • ACR Convergence 2021

    Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE Activity

    Jennifer Rogers1, Rory Bloch2, Amanda Eudy1, David Pisetsky3, Roberta Alexander2, John Conklin2, Kai Sun1, Rebecca Sadun1, Lisa Criscione-Schreiber4, Jayanth Doss1 and Megan Clowse5, 1Duke University, Durham, NC, 2Exagen Inc., Vista, CA, 3Duke University Medical Center, Durham, NC, 4Duke University School of Medicine, Durham, NC, 5Duke University, Chapel Hill, NC

    Background/Purpose: SLE is a multisystem autoimmune disease that displays diverse manifestations that can be categorized into two broad types. Type 1 SLE activity includes inflammatory…
  • Abstract Number: 1207 • ACR Convergence 2021

    A Systematic Review Looking at the Relationship Between Serum Calprotectin and Ultrasound Parameters in Rheumatoid Arthritis

    Andrea Hui Ling Low1, Fang Yi Lim2 and Margaret Ma3, 1National University of Singapore, Singapore, Singapore, 2National Univeristy of Singapore, Singapore, Singapore, 3National University Hospital, Singapore, Singapore

    Background/Purpose: Serum Calprotectin level has been shown to correlate with disease activity, ultrasound (US) parameters, treatment response and clinical remission in rheumatoid arthritis (RA). The…
  • « Previous Page
  • 1
  • …
  • 39
  • 40
  • 41
  • 42
  • 43
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology